Adverse events occurring in >4% of patients taking TYVASO and more frequently than placebo in the pivotal trial (N=235)*†
ADVERSE EVENTS IN THE TRIUMPH STUDY1
- Of the 23 total discontinuations, 7 patients in the TYVASO group discontinued due to adverse events, compared to 4 in the placebo group1
- In addition, adverse events occurring in ≥10% of patients were dizziness and diarrhea2
*Not a comprehensive list.
†More than 3% greater than placebo.
IMPORTANT PATIENT CONSIDERATIONS
BEFORE PRESCRIBING TYVASO, YOU WILL NEED TO KNOW ALL OF YOUR PATIENT'S MEDICAL CONDITIONS, INCLUDING2:
- Lung disease, such as asthma or chronic obstructive pulmonary disease (COPD)
- Lung infection
- Liver problems or kidney problems
- Low blood pressure
- Bleeding problems
- Pregnancy or plans to become pregnant. It is not known if TYVASO will harm an unborn baby
- Breastfeeding or plans to breastfeed. It is not known if TYVASO passes into breast milk. Talk to patients about the best way to feed a baby during treatment with TYVASO.
TYVASO and other medicines may affect each other, so know all of your patient’s prescription and non-prescription medicines, vitamins, and herbal supplements.
Make sure to ask patients if they take any of these medications2:
- Antihypertensives or other drugs for heart disease
- Gemfibrozil or other CYP2C8 inhibitors
- Rifampin or other CYP2C8 inducers
It is not known if TYVASO is safe or effective in people under 18 years of age.